Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 5/20 | 0.77 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384793 | 1.00 | LIMK1 (0.77) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL16751134 | 1.00 | LIMK1 (0.77) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL5629554 | 1.00 | LIMK1 (0.77) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL15241911 | 0.91 | LIMK1 (0.64) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL20259366 | 0.89 | LIMK1 (0.60) | LIMK1MKNK1MAPTCSNK2A2CSNK2B | |
| SCHEMBL16384778 | 0.88 | LIMK1 (0.78) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL29400963 | 0.87 | LIMK1 (1.00) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL20419781 | 0.87 | LIMK1 (1.00) | LIMK1MKNK1P2RX3MAPTPDK1 | |
| SCHEMBL14459798 | 0.83 | LIMK1 (0.54) | LIMK1MKNK1MAPTTP53CSNK2A2 | |
| SCHEMBL16371779 | 0.83 | LIMK1 (0.59) | LIMK1MKNK1MAPTCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233866-B1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20170197979-A1 | BENZOTHIADIAZOLAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197979-A1 | BENZOTHIADIAZOLAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| WO-2017081003-A1 | SUBSTITUTED PYRAZOLOPYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | WO | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-2852595-B1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2015181104-A1 | BENZOTHIADIAZOLAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| WO-2015074986-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | WO | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014118229-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197979-A1 | BENZOTHIADIAZOLAMINES | HIF1AN, PGF, EGLN2 | LIMK1 3417/4885MKNK1 3767/4885P2RX3 1732/4885 |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | CCNA1, CCNT2, TYMP | LIMK1 4038/4885MKNK1 4342/4885P2RX3 743/4885 |
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | LIMK1 3711/4885MKNK1 2721/4885P2RX3 667/4885 |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, DTYMK | LIMK1 504/4885MKNK1 1/4885P2RX3 2325/4885 |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | DPYD, PGF, VEGFA | LIMK1 2545/4885MKNK1 2345/4885P2RX3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.